Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
- DOI
- 10.1007/s12325-024-02822-z
- Published
- 2024-03-18
- Container
- Adv Ther
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-024-02822-z,
title = {Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.},
author = {Salles G and Chen JMH and Zhang I and Kerbauy F and Wu JJ and Wade SW and Nunes A and Feng C and Kloos I and Peng W and Snider JT and Maciel D and Chan K and Keeping S and Shah B.},
year = {2024},
journal = {Adv Ther},
doi = {10.1007/s12325-024-02822-z},
url = {https://doi.org/10.1007/s12325-024-02822-z}
}RIS
TY - JOUR TI - Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. AU - Salles G AU - Chen JMH AU - Zhang I AU - Kerbauy F AU - Wu JJ AU - Wade SW AU - Nunes A AU - Feng C AU - Kloos I AU - Peng W AU - Snider JT AU - Maciel D AU - Chan K AU - Keeping S AU - Shah B. PY - 2024 JO - Adv Ther DO - 10.1007/s12325-024-02822-z UR - https://doi.org/10.1007/s12325-024-02822-z ER -
APA
G, S., JMH, C., I, Z., F, K., JJ, W., SW, W., A, N., C, F., I, K., W, P., JT, S., D, M., K, C., S, K., & B., S. (2024). Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.. Adv Ther. https://doi.org/10.1007/s12325-024-02822-z
Source records
- europe-pmc · retrieved 2026-09-26T18:00:21.309Z